CL2020002507A1 - Variantes de lfa3 y composiciones y usos de las mismas - Google Patents

Variantes de lfa3 y composiciones y usos de las mismas

Info

Publication number
CL2020002507A1
CL2020002507A1 CL2020002507A CL2020002507A CL2020002507A1 CL 2020002507 A1 CL2020002507 A1 CL 2020002507A1 CL 2020002507 A CL2020002507 A CL 2020002507A CL 2020002507 A CL2020002507 A CL 2020002507A CL 2020002507 A1 CL2020002507 A1 CL 2020002507A1
Authority
CL
Chile
Prior art keywords
lfa3
variants
compositions
polypeptide molecules
provides
Prior art date
Application number
CL2020002507A
Other languages
English (en)
Inventor
Natasha Kay Crellin
Lauren Kate Ely
Jason Robles Reyes
Chia Chi Ho
Jeffrey A Bluestone
Eleonora Trotta
Qizhi Tang
Original Assignee
Pfizer
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Univ California filed Critical Pfizer
Publication of CL2020002507A1 publication Critical patent/CL2020002507A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70507—C2D

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)

Abstract

La invención proporciona las moléculas de polipéptido LFA3, por ejemplo, moléculas de polipéptido de fusión LFA3 variantes. La invención incluye usos, y métodos asociados para usar las moléculas de polipéptido LFA3.
CL2020002507A 2018-03-29 2020-09-28 Variantes de lfa3 y composiciones y usos de las mismas CL2020002507A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650022P 2018-03-29 2018-03-29
US201862783986P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
CL2020002507A1 true CL2020002507A1 (es) 2021-02-26

Family

ID=66049729

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002507A CL2020002507A1 (es) 2018-03-29 2020-09-28 Variantes de lfa3 y composiciones y usos de las mismas

Country Status (18)

Country Link
US (2) US12103958B2 (es)
EP (1) EP3774863A1 (es)
JP (2) JP2021519758A (es)
KR (1) KR102826439B1 (es)
CN (1) CN112236446A (es)
AU (2) AU2019242451B2 (es)
BR (1) BR112020019368A2 (es)
CA (1) CA3094756A1 (es)
CL (1) CL2020002507A1 (es)
CO (1) CO2020013557A2 (es)
IL (1) IL277441B2 (es)
MX (2) MX2020010183A (es)
MY (1) MY206031A (es)
PE (2) PE20211235A1 (es)
PH (1) PH12020551582A1 (es)
SG (1) SG11202009539XA (es)
WO (1) WO2019190984A1 (es)
ZA (1) ZA202005875B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079046A1 (en) * 2022-10-10 2024-04-18 Zelarion Malta Limited Anti-cd2 antibodies for type 1 diabetes
WO2025231445A1 (en) * 2024-05-03 2025-11-06 Sonoma Biotherapeutics, Inc. Methods of using lfa3-fc fusion proteins

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
AU660312B2 (en) 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0786255B1 (en) * 1991-10-07 2001-12-12 Biogen, Inc. Methods of improving allograft or xenograft tolerance by administration of an LFA-3 or CD2 binding protein
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DK0885002T3 (da) 1996-03-04 2011-08-22 Penn State Res Found Materialer og fremgangsmåder til forøgelse af cellulær internalisering
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
IL141486A0 (en) * 1998-08-31 2002-03-10 Biogen Inc Pharmaceutical compositions containing a cd2 binding agent
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP2004527477A (ja) * 2001-02-01 2004-09-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｄ２結合因子を用いた、皮膚障害を処置または予防するための方法
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
CN101979650B (zh) 2003-10-22 2015-09-16 凯克研究生院 使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CN101089180A (zh) * 2006-04-26 2007-12-19 上海中信国健药业有限公司 一种重组lfa3基因,及其融合基因与产物
CN101679966B (zh) 2007-01-24 2014-03-12 协和发酵麒麟株式会社 具有增强的效应子活性的遗传重组抗体组合物
KR101950520B1 (ko) 2010-08-05 2019-02-20 시애틀 지네틱스, 인크. 푸코스 유사체를 사용한 생체 내에서의 단백질 푸코실화 억제 방법
WO2014025198A2 (ko) * 2012-08-09 2014-02-13 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도
KR20140021799A (ko) * 2012-08-09 2014-02-20 주식회사 한독 Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도

Also Published As

Publication number Publication date
CN112236446A (zh) 2021-01-15
US20210032308A1 (en) 2021-02-04
IL277441B2 (en) 2026-01-01
IL277441A (en) 2020-11-30
MX2020010183A (es) 2022-11-28
JP2021519758A (ja) 2021-08-12
PE20251751A1 (es) 2025-07-09
PE20211235A1 (es) 2021-07-08
IL277441B1 (en) 2025-09-01
AU2024205663A1 (en) 2024-08-29
ZA202005875B (en) 2025-01-29
EP3774863A1 (en) 2021-02-17
MX2022014899A (es) 2023-01-04
JP2025060698A (ja) 2025-04-10
KR20200136465A (ko) 2020-12-07
AU2019242451B2 (en) 2024-05-09
AU2019242451A1 (en) 2020-11-12
WO2019190984A1 (en) 2019-10-03
CO2020013557A2 (es) 2020-11-10
US20250163125A1 (en) 2025-05-22
BR112020019368A2 (pt) 2021-02-17
SG11202009539XA (en) 2020-10-29
US12103958B2 (en) 2024-10-01
PH12020551582A1 (en) 2021-09-13
MY206031A (en) 2024-11-26
KR102826439B1 (ko) 2025-06-26
CA3094756A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
CO2022008406A2 (es) Degradadores de irak y usos de los mismos
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CL2020003255A1 (es) Proteínas de fusión que comprenden progranulina
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
MX392605B (es) Compuestos, composiciones y metodos para el tratamiento de enfermedades.
CL2019002251A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX390120B (es) Moduladores de la somatostatina y usos de los mismos.
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.
BR112022012230A2 (pt) Variantes de progranulina
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2021004925A (es) Variantes de adn-polimerasa modificadas.
BR112016025450A2 (pt) moduladores de canais de íons e usos dos mesmos
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos
CL2020002507A1 (es) Variantes de lfa3 y composiciones y usos de las mismas
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2021013117A (es) Composiciones y metodos para el tratamiento del cancer.